S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
Log in
NASDAQ:NTLA

Intellia Therapeutics Stock Forecast, Price & News

$24.95
+0.55 (+2.25 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$23.89
Now: $24.95▼
$25.34
50-Day Range
$17.47
MA: $22.56▼
$26.31
52-Week Range
$9.18
Now: $24.95▼
$27.07
Volume490,979 shs
Average Volume858,955 shs
Market Capitalization$1.47 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.69
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Ospedale San Raffaele; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Intellia Therapeutics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.38 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTLA
Previous Symbol
CUSIPN/A
CIK1652130
Webwww.intelliatx.com
Phone857-285-6200
Employees211

Debt

Debt-to-Equity RatioN/A
Current Ratio7.55
Quick Ratio7.55

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$43.10 million
Price / Sales34.00
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.52 per share
Price / Book4.52

Profitability

EPS (Most Recent Fiscal Year)($2.11)
Net Income$-99,530,000.00
Net Margins-228.87%
Return on Equity-40.57%
Return on Assets-31.24%

Miscellaneous

Outstanding Shares58,741,000
Market Cap$1.47 billion
Next Earnings Date10/29/2020 (Estimated)
OptionableOptionable
$24.95
+0.55 (+2.25 %)
(As of 10/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

How has Intellia Therapeutics' stock price been impacted by Coronavirus?

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NTLA shares have increased by 96.1% and is now trading at $24.95.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Intellia Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Intellia Therapeutics.

When is Intellia Therapeutics' next earnings date?

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Intellia Therapeutics.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics Inc (NASDAQ:NTLA) announced its earnings results on Thursday, August, 6th. The company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.08. The business had revenue of $16.26 million for the quarter, compared to analysts' expectations of $9.52 million. Intellia Therapeutics had a negative net margin of 228.87% and a negative return on equity of 40.57%. The business's revenue was up 46.3% on a year-over-year basis. During the same period last year, the business earned ($0.56) earnings per share.
View Intellia Therapeutics' earnings history.

What price target have analysts set for NTLA?

11 equities research analysts have issued 12 month price targets for Intellia Therapeutics' shares. Their forecasts range from $20.00 to $57.50. On average, they anticipate Intellia Therapeutics' stock price to reach $30.44 in the next twelve months. This suggests a possible upside of 22.0% from the stock's current price.
View analysts' price targets for Intellia Therapeutics.

Who are some of Intellia Therapeutics' key competitors?

Some companies that are related to Intellia Therapeutics include Neogen (NEOG), Heska (HSKA), Myriad Genetics (MYGN), Meridian Bioscience (VIVO), Lantheus (LNTH), Celldex Therapeutics (CLDX), Quotient (QTNT), Aspira Women's Health (AWH), Vermillion (VRML), Oxford Immunotec Global (OXFD), Riot Blockchain (RIOT), VolitionRx (VNRX), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX) and OncoCyte (OCX).
View all competitors.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), InVitae (NVTA) and Cisco Systems (CSCO).

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the following people:
  • Dr. John M. Leonard, Pres, CEO & Director (Age 62)
  • Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 46)
  • Mr. José E. Rivera, Exec. VP & Gen. Counsel (Age 53)
  • Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 33)
  • Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Dupont Capital Management Corp (0.05%), DAVENPORT & Co LLC (0.03%), DekaBank Deutsche Girozentrale (0.03%), Pacer Advisors Inc. (0.00%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, John M Leonard and Jose E Rivera.
View institutional ownership trends for Intellia Therapeutics.

Which major investors are selling Intellia Therapeutics stock?

NTLA stock was sold by a variety of institutional investors in the last quarter, including Dupont Capital Management Corp. Company insiders that have sold Intellia Therapeutics company stock in the last year include John M Leonard, and Jose E Rivera.
View insider buying and selling activity for Intellia Therapeutics.

Which major investors are buying Intellia Therapeutics stock?

NTLA stock was acquired by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC, DekaBank Deutsche Girozentrale, Pacer Advisors Inc., and Nisa Investment Advisors LLC.
View insider buying and selling activity for Intellia Therapeutics.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $24.95.

How big of a company is Intellia Therapeutics?

Intellia Therapeutics has a market capitalization of $1.47 billion and generates $43.10 million in revenue each year. The company earns $-99,530,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Intellia Therapeutics employs 211 workers across the globe.

What is Intellia Therapeutics' official website?

The official website for Intellia Therapeutics is www.intelliatx.com.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.